Authors : Dr. Syeda Neha Fatima; Fatima Umaira Saeed; Mariya Sana

Volume/Issue : Volume 10 - 2025, Issue 9 - September

Google Scholar : https://tinyurl.com/yc2p5cm3

Scribd : https://tinyurl.com/4kjvfc5y

DOI : https://doi.org/10.38124/ijisrt/25sep335

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Hypertension remains the leading preventable risk factor for cardiovascular and renal morbidity worldwide, affecting nearly one-third of adults. Its etiopathogenesis is multifactorial, involving genetic predisposition, neurohormonal dysregulation, renal dysfunction, vascular remodeling, metabolic abnormalities, and environmental influences. Recent advances in diagnostics—including ambulatory blood pressure monitoring, wearable sensors, artificial intelligence, and biomarker discovery—have improved early detection and risk stratification. Pharmacotherapy continues to evolve beyond traditional agents such as thiazides, ACE inhibitors, ARBs, and calcium-channel blockers, with novel drugs including endothelin receptor antagonists, aldosterone synthase inhibitors, RNA interference therapies, and nonsteroidal mineralocorticoid receptor antagonists showing promising results in resistant and high-risk populations. Non- pharmacological strategies, including sodium restriction, weight reduction, physical activity, and the DASH diet, remain the cornerstone of management and prevention. Population-level interventions, precision medicine approaches, and digital health integration further enhance control and adherence. Collectively, these innovations highlight a paradigm shift toward individualized, multi-modal hypertension care, aimed at reducing the persistent global burden of cardiovascular complications.

Keywords : Hypertension, Endothelin Receptor Antagonists, Lifestyle Modification, DASH Diet.

References :

1. Carretero OA, Oparil S. Essential hypertension. Circulation Res. 2000;86(5):1049-51. doi:10.1002/cphy.c110058
2. Whelton PK, Carey RM. The 2017 clinical practice guideline for high blood pressure. J Hypertens. 2018;36(6):1103-42. doi:10.1097/HJH.0000000000001941
3. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Lancet. 2020;395(10234):801-15. doi:10.1016/S0140-6736(21)00221-X
4. Daugherty A, Cassis LA. Mechanisms of hypertension. Hypertension. 2015;65(5):940-5. doi:10.1161/HYPERTENSIONAHA.115.05631
5. Hall JE. The kidney, hypertension, and obesity. Compr Physiol. 2012;2(2):811-56. doi:10.1002/cphy.c110058
6. Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension. Circ Res. 2017;120(4):659-79. doi:10.1161/RES.000000000000009
7. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over one million people identifies 535 new loci associated with blood pressure traits. Hum Mol Genet. 2018;28(4):597-616. doi:10.1093/hmg/ddz024
8. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. PLoS Comput Biol. 2012;8(8):e1003. doi:10.1371/journal.pcbi.1003
9. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Heart disease and stroke statistics—2015 update. Circ Res. 2015;116(1):e25-146. doi:10.1161/CIRCRESAHA.115.305755
10. Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? Lancet. 2021;397(10293):1807-9. doi:10.1016/S0140-6736(21)00221-X
11. Zhang J, Crowley SD. The role of the renin-angiotensin-aldosterone system in cardiovascular disease. Int J Mol Sci. 2022;22(14):7310. doi:10.3390/ijms22147310
12. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Mancia G. Sympathetic and baroreflex function in hypertension. Hypertension. 2018;71(3):430-6. doi:10.1161/HYPERTENSIONAHA.115.05631
13. Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: EDCFs. Circ Res. 2015;116(11):173-89. doi:10.1161/RES.000000000000009
14. Hall JE, Guyton AC, Brands MW. Pressure–natriuresis and long-term blood pressure regulation. Hypertension. 2005;46(3):477-85. doi:10.1161/01.HYP.23.3.381
15. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356(19):1966-78. doi:10.1056/NEJMra065394
16. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Am J Physiol Heart Circ Physiol. 2019;316(5):H1205-22. doi:10.1152/ajpheart.00506.2018
17. Friedman O, Bradley TD, Logan AG. Influence of sleep apnea on mortality in patients with hypertension. Circulation. 2017;135(8):701-9. doi:10.1161/CIRCULATIONAHA.116.022968
18. Rodriguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ. The immunological basis of hypertension. Hypertension. 2005;45(4):662-8. doi:10.1161/01.HYP.0000152867.74745.34
19. Pettersen KH, Bugenhagen SM, Nauman J, Beard DA, Omholt SW. Arterial stiffening provides sufficient explanation for primary hypertension. PLoS Comput Biol. 2013;9(5):e1003008. doi:10.1371/journal.pcbi.1003008
20. Li J, Zhao F, Wang Y, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14. doi:10.1186/s40168-016-0222-x
21. Thomas G, Shishehbor M, Bravo E, Nally JV. Secondary hypertension: discovery, diagnosis, and management. World J Hypertens. 2015;5(2):14-26. doi:10.5494/wjh.v5.i2.14
22. Williams B, Mancia G, Spiering W, et al. 2020 International Society of Hypertension global practice guidelines for the management of hypertension. Hypertension. 2020;75(6):1334-57. doi:10.1161/HYPERTENSIONAHA.120.15026
23. Muhammad Iqbal A, et al. Essential hypertension: pathophysiology and management. Hypertension. 2023;81(2):345-58. doi:10.1161/HYPERTENSIONAHA.120.15026
24. Williams B, Mancia G, Spiering W, et al. 2020 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2020;41(38):375-469. doi:10.1161/HYPERTENSIONAHA.120.15026
25. Monticone S, Burrello J, Tizzani D, et al. Primary aldosteronism: an update on screening, diagnosis and treatment. Ther Adv Endocrinol Metab. 2006;7(1):13-23. doi:10.1177/2042018820930815
26. Sarathy H, Carey RM. Secondary hypertension: renovascular, endocrine, and sleep apnea causes. Med Clin North Am. 2022;106(3):433-52. doi:10.1016/j.mcna.2021.11.004
27. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Hypertension. 2016;67(3):467-75. doi:10.1161/HYPERTENSIONAHA.116.022968
28. Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of hypertension. Hypertension. 2018;72(3):467-77. doi:10.1161/HYPERTENSIONAHA.113.02741
29. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. N Engl J Med. 2003;289(19):2560-72. doi:10.1056/NEJMra020530
30. Wu J, Kraja AT, Oberman A, et al. Hypertensive retinopathy revisited: classification, pathophysiology, and clinical relevance. Br Med Bull. 2009;90(1):5-30. doi:10.1016/j.brmedbull.2009.05.001
     
31. Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of hypertensive encephalopathy. Hypertension. 2014;63(5):1080-6. doi:10.1161/01.HYP.0000152867.74745.34
32. Vongpatanasin W. Hypertension crises: urgency and emergency. J Am Coll Cardiol. 2017;71(7):739-50. doi:10.1016/j.jacc.2017.02.001
33. Roberts JM, August PA, Bakris G, et al. Hypertension in pregnancy. Hypertension. 2013;62(5):1026-31. doi:10.1161/HYPERTENSIONAHA.111.002878
34. Katz DH, Burns JA, Aguilar FG, et al. Left ventricular hypertrophy in hypertension: clinical implications. Circ Res. 2015;116(6):1061-73. doi:10.1161/CIRCRESAHA.115.305755
35. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes. N Engl J Med. 2014;371(7):603-15. doi:10.1056/NEJMra140575
36. Parati G, Stergiou G, Dolan E, Bilo G. Masked hypertension. In: Hypertension: A Companion to Braunwald’s Heart Disease. 3rd ed. Philadelphia: Elsevier; 2024. p. 163-74. doi:10.1016/B978-0-323-88369-6.00012-8
37. Omboni S, Palatini P, Parati G. White-coat hypertension: pathophysiological and clinical aspects. Hypertension. 2011;58(5):784-90. doi:10.1161/HYPERTENSIONAHA.113.02741
38. Peixoto AJ. Acute severe hypertension. Hypertension. 2005;45(2):193-200. doi:10.1161/01.HYP.23.3.381
39. Kario K, Hoshide S, Chia YC, et al. Nocturnal blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2019;73(2):233-9. doi:10.1161/HYPERTENSIONAHA.118.11314
40. Bousser MG, Amarenco P. Headache and hypertension: clinical association and management. Cephalalgia. 2009;29(9):1103-10. doi:10.1177/0333102409105400
41. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73(5):e35-66. doi:10.1161/HYPERTENSIONAHA.119.12624
42. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940
43. Shimbo D, Artinian NT, Basile JN, et al. Self-measured blood pressure monitoring at home: a joint policy statement. Hypertension. 2020;76(3):854-72. doi:10.1161/HYPERTENSIONAHA.120.14742
44. Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability and home monitoring. J Hypertens. 2021;39(1):19-25. doi:10.1097/HJH.0000000000002746
45. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13-115. doi:10.1161/HYP.0000000000000065
46. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-90. doi:10.1161/HYP.0000000000000066
47. Kjeldsen SE, Os I, Hoieggen A, Beckey J, Gleim GW, Oparil S. Target organ damage in hypertension: left ventricular hypertrophy, arterial thickening, and microalbuminuria. J Hypertens. 2014;32(2):248-60. doi:10.1097/HJH.0000000000000061
48. Monticone S, Burrello J, Tetti M, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. Lancet Diabetes Endocrinol. 2018;6(6):464-76. doi:10.1016/S0140-6736(18)30947-9
49. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484
50. Shimbo D, Artinian NT, Basile JN, et al. Self-measured blood pressure monitoring at home: a joint policy statement. Hypertension. 2020;76(3):854-72. doi:10.1161/HYPERTENSIONAHA.120.14742
51. Mukkamala R, Hahn JO, Inan OT, et al. Toward ubiquitous blood pressure monitoring via pulse transit time: theory and practice. IEEE J Biomed Health Inform. 2015;19(1):75-88. doi:10.1109/JBHI.2015.2408597
52. Slapničar G, Mlakar N, Luštrek M. Blood pressure estimation from photoplethysmogram using a spectro-temporal deep neural network. IEEE J Biomed Health Inform. 2019;23(6):2106-13. doi:10.1109/JBHI.2019.2897272
53. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Hypertens. 2015;33(12):2370-9. doi:10.1097/HJH.0000000000000530
54. Juraschek SP, Miller ER, Weaver CM, Appel LJ. Effects of sodium reduction and the DASH diet in relation to baseline blood pressure. Hypertension. 2021;77(2):397-407. doi:10.1161/HYPERTENSIONAHA.120.14718
55. Niiranen TJ, Johansson JK, Reunanen A, Jula AM. Masked and white-coat hypertension: diagnostic issues. J Hypertens. 2019;37(5):827-36. doi:10.1097/HJH.0000000000002181
56. Cho JH, Lee HJ, Lim YG, et al. Artificial intelligence algorithm for predicting hypertension using electrocardiography. Nat Med. 2021;27(5):910-6. doi:10.1038/s41591-020-01197-2
57. Kontaraki JE, Marketou ME, Zacharis EA, et al. MicroRNA profiling in hypertensive patients: a new approach for diagnosis and treatment. J Hypertens. 2014;32(1):217-22. doi:10.1097/HJH.0000000000000192
58. Kario K, Nomura A, Harada N, et al. Digital therapeutics for hypertension: expanding evidence and potential application. Hypertension. 2020;76(5):1334-43. doi:10.1161/HYPERTENSIONAHA.120.14716
59. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018 Jun;71(6):e13–115. https://doi.org/10.1161/HYP.0000000000000065
60. Williams B, Masi S, Wolf J, Schmieder RE. Facing the challenge of lowering blood pressure and cholesterol in the same patient: report of a symposium at the European Society of Hypertension. J Hypertens. 2023 Jun;41(6):1115–25. https://doi.org/10.1097/HJH.0000000000003480
61. Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. JAMA Intern Med. 2020 Nov;180(11):1552–60. https://doi.org/10.1001/jamainternmed.2020.0278
62. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec;288(23):2981–97. https://doi.org/10.1001/jama.288.23.2981
63. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep;366(9489):895–906. https://doi.org/10.1016/S0140-6736(05)67185-1
64. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar;359(9311):995–1003. https://doi.org/10.1016/S0140-6736(02)07923-1
65. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec;359(23):2417–28. https://doi.org/10.1056/NEJMoa0806182
66. Parati G, Kjeldsen SE, Coca A, Cushman WC, Wang J, Schiffrin EL, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021 Feb;77(2):692–705. https://doi.org/10.1161/HYPERTENSIONAHA.120.15781
67. Joseph P, Roshandel G, Gao P, Pais P, Avezum A, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021 Sep;398(10306):1133–46. https://doi.org/10.1016/S0140-6736(21)01827-4
68. Castellano JM, Pocock SJ, Bhatt DL, Owen R, Weinstein JL, Sanchez PA, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022 Sep;387(11):967–77. https://doi.org/10.1056/NEJMoa2208275
69. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov;373(22):2103–16. https://doi.org/10.1056/NEJMoa1511939
70. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 May;358(18):1887–98. https://doi.org/10.1056/NEJMoa0801369
71. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin–angiotensin system blockade on calcium channel blocker–associated peripheral edema. Am J Med. 2011 Dec;124(12):128–35. https://doi.org/10.1016/j.amjmed.2011.02.036
    Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov;386(10008):2059–68. https://doi.org/10.1016/S0140-6736(15)00257-3
72. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021 Dec;385(26):2507–19. https://doi.org/10.1056/NEJMoa2100743
73. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Nov;394(10208):1540–8. https://doi.org/10.1016/S0140-6736(19)32135-X
74. Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec;367(23):2204–13. https://doi.org/10.1056/NEJMoa1112787
75. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Lancet. 2007 May;369(9569):1431–6. https://doi.org/10.1016/S0140-6736(07)60142-1
76. Choi HK, Soriano LC, Zhang Y, Rodríguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012 Jan;344:d8190. https://doi.org/10.1136/bmj.d8190
77. Magee LA, von Dadelszen P. State-of-the-art diagnosis and treatment of hypertension in pregnancy. Mayo Clin Proc. 2022 Sep;97(9):1659–74. https://doi.org/10.1016/S0140-6736(19)32417-0
78. Chow CK, Thakkar J, Bennett A, Hillis GS, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension (QUARTET): a randomised, double-blind, parallel-group, multicentre trial. Lancet. 2021 Sep;398(10305):1043–52. https://doi.org/10.1016/S0140-6736(21)01922-X
79. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. Heart. 2020;106(17):1301–10. https://doi.org/10.1136/heartjnl-2019-315980
80. Smith SM, Gong Y, Handberg E, Pepine CJ. SGLT2 inhibitors in hypertension management: current evidence and future perspectives. J Clin Med. 2024;13(7):1587. https://doi.org/10.3390/jcm13071587
81. Naseralallah LM, Elshourbagy NA, Farhan HA, Ibrahim MS. Aprocitentan: a novel endothelin receptor antagonist in resistant hypertension. Blood Press. 2024;33(4):245–52. https://doi.org/10.1080/08037051.2024.2424824
82. Ferdinand KC. Lorundrostat: a promising aldosterone synthase inhibitor for resistant hypertension. J Hypertens. 2025;43(2):e110–12. doi pending.
83. Blazek C, Bakris GL. Firibastat and the brain renin–angiotensin system: a novel approach to blood pressure lowering. J Hypertens. 2023;41(5):899–907. https://doi.org/10.1097/HJH.0000000000000192
84. Carvalho R, Camporez JP, Krieger JE, Williams GH, Pfeffer MA. Zilebesiran, an siRNA targeting angiotensinogen, in hypertension. Nat Med. 2023;29:1055–63. https://doi.org/10.1038/s41591-023-02668-0
85. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular outcomes with finerenone in chronic kidney disease and type 2 diabetes. Hypertension. 2021;78(5):1042–52. https://doi.org/10.1097/HYP.0000000000000530
86. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of KBP-5074, a nonsteroidal mineralocorticoid receptor antagonist, in advanced chronic kidney disease. Hypertension. 2021;77(6):1794–803. https://doi.org/10.1161/HYPERTENSIONAHA.121.315472
87. Wang Y, Li J, Zhang H, Zhao X, Chen J, Xu T, et al. Discovery of MT-1207, a multitarget inhibitor with antihypertensive efficacy. J Med Chem. 2024;67(10):6125–37. https://doi.org/10.1021/acs.jmedchem.4c00626
88. Jiang Y, Chen L, Zhang X, Wu J. Phosphodiesterase-5 inhibitors and guanylate cyclase stimulators: novel directions in hypertension therapy. Eur J Med Chem. 2024;261:116593. https://doi.org/10.1016/j.ejmech.2024.116593
89. Fan Y, Zhao Y, Li X, Xu H, Wang J. Transdermal nanosystems for antihypertensive therapy: advances and perspectives. Drug Dev Ind Pharm. 2024;50(3):221–32. https://doi.org/10.1080/10837450.2024.2324981
90. Zhang J, Liu Y, Wang C, Sun H, Xu L, Zhao J, et al. Hypertension vaccines: a new frontier in immunotherapy. Front Cardiovasc Med. 2022;9:1003852. https://doi.org/10.3389/fcvm.2022.1003852
91. George J, Wong G, Rogers K, Patel A, Webster R. A next-generation polypill for hypertension: the GMRx2 trial. Lancet. 2024;403(10379):100–10. https://doi.org/10.1016/S0140-6736(24)00001-2
92. Ferdinand KC. Low-dose triple combination therapy for hypertension: insights from meta-analysis. J Hypertens. 2025;43(3):e220–22. doi pending.
93. Shi J, Li J, Zhao Y, Liu Y, Liu J. Artificial intelligence–driven precision medicine in hypertension management. Hypertension. 2019;74(6):1222–30. https://doi.org/10.1161/HYPERTENSIONAHA.119.13437
94. Brown MJ, Williams B, Calhoun DA, Lenders JWM. Targeted thermal therapy for primary aldosteronism: a potential curative approach. Lancet. 2025;405(10392):120–28. doi pending.
95. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018 Jun;71(6):e13–115. doi:10.1161/HYP.0000000000000065
96. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997 Apr 17;336(16):1117–24. doi:10.1056/NEJM199704173361601
97. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013 Apr 3;346:f1325. doi:10.1136/bmj.f1325
98. Filippini T, Malavolti M, Whelton PK, Naska A, Orsini N, Vinceti M. Blood pressure effects of potassium supplementation: a meta-analysis of randomized controlled trials. Am J Hypertens. 2020 Dec;33(12):1136–44. doi:10.1093/ajh/hpaa036
99. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. N Engl J Med. 2001 May 3;344(18):1343–50. doi:10.1056/NEJM200105033441801
100. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. Hypertension. 2013 Dec;61(4): 1049–55. doi:10.1161/HYPERTENSIONAHA.112.02173
101. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet. 2017 Mar 4;389(10065):781–94. doi:10.1016/S0140-6736(16)32420-2
102. Primatesta P, Falaschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure: evidence from the health survey for England. Int J Epidemiol. 2001 Jun;30(3):590–6. doi:10.1093/ije/30.3.590
103. Park SH, Han KS, Kang CB. Effects of exercise programs on depressive symptoms, quality of life, and self-esteem in older people: a systematic review of randomized controlled trials. J Hypertens. 2014 Jan;32(1):174–84. doi:10.1097/HJH.0000000000000125
104. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Respir Care Med. 2011 Oct;183(12):1632–9. doi:10.1164/rccm.201012-2010OC
105. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension. 2013 Jun;61(6):1360–83. doi:10.1161/HYP.0b013e318293645f
106. Charchar FJ, Samani NJ. Prevention of hypertension: translating genetics and lifestyle into population benefit. J Hypertens. 2023 Apr;41(4):623–5. doi:10.1097/HJH.0000000000003563
107. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovás JM, Ruilope LM, Lucia A. Lifestyle interventions for the prevention and treatment of hypertension. Nat Rev Cardiol. 2021 Apr;18(4):251–75. doi:10.1038/s41569-020-00437-9
108. Filippou CD, Tsioufis C, Thomopoulos C, Mihas C, Dimitriadis K, Sotiropoulou LI, et al. Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction: meta-analysis of randomized controlled trials. Adv Nutr. 2020 Jul;11(5):1150–60. doi:10.1093/advances/nmaa041
109. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013 Apr 3;346:f1325. doi:10.1136/bmj.f1325
110. Juraschek SP, Miller ER, Weaver CM, Appel LJ. Effects of sodium reduction and the DASH diet in relation to baseline blood pressure. J Am Coll Cardiol. 2017 Dec 12;70(23):2841–8. doi:10.1016/j.jacc.2017.10.011
111. Pescatello LS, Buchner DM, Jakicic JM, Powell KE, Kraus WE, Bloodgood B, et al. Physical activity to prevent and treat hypertension: a systematic review. Med Sci Sports Exerc. 2019 Nov;51(6):1314–23. doi:10.1249/MSS.0000000000001943
112. Semlitsch T, Jeitler K, Berghold A, Horvath K, Posch N, Poggenburg S, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2021 Mar 16;3(3):CD008274. doi:10.1002/14651858.CD008274.pub4
113. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017 Jul;2(7):e108–20. doi:10.1016/S2468-2667(17)30003-8
114. Gaya DR, Kaleta D, Osińska M, Zielińska-Danch W. Effectiveness of smoking cessation interventions on arterial blood pressure in hypertensive smokers. Tob Induc Dis. 2024 Jan;22:13. doi:10.18332/tid/186853
115. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovás JM, Ruilope LM, Lucia A. Lifestyle interventions for the prevention and treatment of hypertension. Nat Rev Cardiol. 2021 Apr;18(4):251–75. doi:10.1038/s41569-020-00437-9
116. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovás JM, Ruilope LM, Lucia A. Lifestyle interventions for the prevention and treatment of hypertension. Nat Rev Cardiol. 2021 Apr;18(4):251–75. doi:10.1038/s41569-020-00437-9
117. He FJ, Li J, MacGregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013 Apr 3;346:f1325. doi:10.1136/bmj.f1325
118. Charchar FJ, Samani NJ. Prevention of hypertension: translating genetics and lifestyle into population benefit. J Hypertens. 2023 Apr;41(4):623–5. doi:10.1097/HJH.0000000000003563